Arvest Bank Trust Division Sells 1,305 Shares of Johnson & Johnson (NYSE:JNJ)

Arvest Bank Trust Division reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87,185 shares of the company’s stock after selling 1,305 shares during the quarter. Arvest Bank Trust Division’s holdings in Johnson & Johnson were worth $12,609,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of JNJ. IFS Advisors LLC raised its position in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the last quarter. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson during the 4th quarter worth about $29,000. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $32,000. Finally, Conquis Financial LLC bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $33,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on JNJ shares. Raymond James cut their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research report on Monday. Wells Fargo & Company dropped their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Leerink Partners decreased their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday. Finally, Morgan Stanley boosted their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday. Nine equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $171.78.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Up 0.2 %

JNJ stock opened at $153.95 on Thursday. The stock has a market cap of $371.00 billion, a price-to-earnings ratio of 23.15, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The company has a fifty day moving average price of $159.40 and a two-hundred day moving average price of $155.10. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.